Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 13 of 13 entries
View as:

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Phase: N/A Priority: Normal
NCT ID: NCT05712538 Org: User:
Start: 02/15/23 End: 07/29/24 Due: 07/29/25

Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults

Phase: N/A Priority: Normal
NCT ID: NCT06279871 Org: User:
Start: 03/27/24 End: 11/21/24 Due: 11/21/25

Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults

Phase: N/A Priority: Normal
NCT ID: NCT06125691 Org: User:
Start: 01/22/24 End: 01/31/25 Due: 01/31/26

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04480957 Org: User:
Start: 08/04/20 End: 01/29/21 Due: 01/29/22

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04416126 Org: User:
Start: 06/01/20 End: 12/09/20 Due: 12/09/21

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT04442347 Org: User:
Start: 11/03/20 End: 04/30/24 Due: 04/30/25

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT04668339 Org: User:
Start: 01/07/21 End: 03/01/22 Due: 03/01/23

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

Phase: N/A Priority: Normal
NCT ID: NCT06602531 Org: User:
Start: 12/12/24 End: 12/19/25 Due: 12/19/26

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

Phase: N/A Priority: Normal
NCT ID: NCT05037097 Org: User:
Start: 08/30/21 End: 12/19/23 Due: 12/19/24

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT06747858 Org: User:
Start: 12/12/24 End: 12/31/25 Due: 12/31/26

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Phase: N/A Priority: Normal
NCT ID: NCT05526066 Org: User:
Start: 07/06/22 End: 11/01/24 Due: 11/01/25

Open Label Extension Study to Assess the Safety and Long-Term Immunogenicity of ARCT-021

Phase: N/A Priority: Normal
NCT ID: NCT04728347 Org: User:
Start: 01/04/21 End: 12/28/21 Due: 12/28/22

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Phase: N/A Priority: Normal
NCT ID: NCT06488313 Org: User:
Start: 11/04/24 End: 09/01/26 Due: 09/01/27